These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37147783)

  • 21. Photo-responsive prodrug nanoparticles for efficient cytoplasmic delivery and synergistic photodynamic-chemotherapy of metastatic triple-negative breast cancer.
    Jiao J; Lu H; Wang S
    Acta Biomater; 2021 May; 126():421-432. PubMed ID: 33774201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-Prodrug-Based Hyaluronic Acid Nanoplatform Provides Cascade-Boosted Drug Delivery for Oxidative Stress-Enhanced Chemotherapy.
    Zhang J; Deng M; Xu C; Li D; Yan X; Gu Y; Zhong M; Gao H; Liu Y; Zhang J; Qu X; Zhang J
    ACS Appl Mater Interfaces; 2024 Sep; 16(38):50459-50473. PubMed ID: 39258403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
    Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
    J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration.
    Son S; Deepagan VG; Shin S; Ko H; Min J; Um W; Jeon J; Kwon S; Lee ES; Suh M; Lee DS; Park JH
    Acta Biomater; 2018 Oct; 79():294-305. PubMed ID: 30134209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy.
    Tian H; Yu L; Zhang M; He J; Sun X; Ni P
    Colloids Surf B Biointerfaces; 2023 Aug; 228():113400. PubMed ID: 37331192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
    Bellavita R; Piccolo M; Leone L; Ferraro MG; Dardano P; De Stefano L; Nastri F; Irace C; Falanga A; Galdiero S
    Int J Nanomedicine; 2024; 19():6057-6084. PubMed ID: 38911501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
    Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
    Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted codelivery of doxorubicin and oleanolic acid by reduction responsive hyaluronic acid-based prodrug nano-micelles for enhanced antitumor activity and reduced toxicity.
    Kong F; Liu H; Zhao C; Qin J
    Int J Biol Macromol; 2024 Oct; 277(Pt 2):134135. PubMed ID: 39069033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
    Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
    Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
    Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
    Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zwitterionic shielded polymeric prodrug with folate-targeting and pH responsiveness for drug delivery.
    Li L; Song Y; He J; Zhang M; Liu J; Ni P
    J Mater Chem B; 2019 Feb; 7(5):786-795. PubMed ID: 32254853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stimuli-responsive polymeric prodrug-based nanomedicine delivering nifuroxazide and doxorubicin against primary breast cancer and pulmonary metastasis.
    Luo L; Xu F; Peng H; Luo Y; Tian X; Battaglia G; Zhang H; Gong Q; Gu Z; Luo K
    J Control Release; 2020 Feb; 318():124-135. PubMed ID: 31838206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Codelivered Chemotherapeutic Doxorubicin
    Lan Y; Liang Q; Sun Y; Cao A; Liu L; Yu S; Zhou L; Liu J; Zhu R; Liu Y
    ACS Appl Mater Interfaces; 2020 Jul; 12(28):31904-31921. PubMed ID: 32551517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
    Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
    ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyethyl starch-folic acid conjugates stabilized theranostic nanoparticles for cancer therapy.
    Wang C; Wang Q; Wang H; Li Z; Chen J; Zhang Z; Zeng H; Yu X; Yang X; Yang X; Li Z
    J Control Release; 2023 Jan; 353():391-410. PubMed ID: 36473606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
    Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
    J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Synergistic Chemoimmunotherapy System Leveraging PD-L1 Blocking and Bioorthogonal Prodrug Activation.
    Wang K; Jiang M; Li T; Liu Y; Zong Q; Xu Q; Ullah I; Chen Y; Xue W; Yuan Y
    Adv Mater; 2024 Jul; 36(30):e2402322. PubMed ID: 38718226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.
    Casazza A; Van Helleputte L; Van Renterghem B; Pokreisz P; De Geest N; De Petrini M; Janssens T; Pellens M; Diricx M; Riera-Domingo C; Wozniak A; Mazzone M; Schöffski P; Defert O; Reyns G; Kindt N
    Mol Cancer Ther; 2022 Apr; 21(4):568-581. PubMed ID: 35149549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer.
    Yi H; Lu W; Liu F; Zhang G; Xie F; Liu W; Wang L; Zhou W; Cheng Z
    J Nanobiotechnology; 2021 May; 19(1):134. PubMed ID: 33975609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.